Eaton to showcase comprehensive commercial vehicle clutch portfolio at Automechanika Frankfurt
5.9.2024 12:30:00 CEST | Business Wire | Press release
Intelligent power management company Eaton today announced it is showcasing an array of aftermarket clutch solutions for the Europe, Middle East and Africa (EMEA) markets at Automechanika Frankfurt in Hall 3, booth D11. Eaton is displaying its complete line of angle spring clutches, diaphragm spring clutches, concentric pneumatic clutch actuators and ServiceRanger diagnostic solutions for commercial vehicles.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240905507731/en/
Eaton’s Advantage series automated diaphragm spring clutches are designed for all makes and models of automated manual transmissions (AMT) in the EMEA market. (Photo: Business Wire)
“We are dedicated to expanding our product portfolio to meet the changing needs of the global market and increasing customer relationships in all market channels,” said Tim Bauer, vice president, Aftermarket, Eaton’s Mobility Group.
The angle spring clutches are used for manual transmissions and are offered in two series. The Advantage series features strap drive technology that improves intermediate plate connection for more reliable performance while eliminating lug rattle and fatigue. Additionally, they are designed with a dual-seal release bearing, which allows for best-in-class 80,000-km lube intervals, reducing maintenance downtime. Eaton also offers the EverTough® series, which provides a more cost-effective solution for vehicles older than seven years.
Eaton also will be displaying its Advantage series automated diaphragm spring clutches for all makes and models of automated manual transmissions (AMT) in the EMEA market. These clutches are built to strict OEM quality standards and minimize idling noise while reducing severe vibrations and delivering outstanding performance and extended clutch life.
Eaton will also be showing its electronic clutch actuator that is designed for its UltraShift Plus transmission along with its concentric pneumatic clutch actuators (CPCAs) for DT12®, the Volvo I-Shift and Mack mDRIVE™ AMTs. The CPCAs help optimize vehicle performance by working with a vehicle’s AMT to continuously determine the ideal release position and clutch actuation when the transmission shifts. Many current AMT-equipped trucks are no longer under factory warranty, so fleet customers need reliable parts to complete repairs and maintenance. Replacing the CPCA during clutch service can help save repair time and cost while reducing downtime for unscheduled maintenance.
To support AMTs operating in the market Eaton offers its ServiceRanger™ 4 Pro Plus (SR4 Pro Plus) software. This diagnostic software and service tool is designed to support all Eaton AMTs, hybrid powertrain systems, Advantage Automated Series clutches and Eaton Cummins Automated Transmission Technologies. In addition, there is an “App Center” that allows users to calibrate all makes and models of diaphragm spring clutches and CPCAs that fit DT12®, Volvo® I-Shift and Mack mDRIVE™ AMTs.
“Eaton now offers a complete line of aftermarket clutch products in EMEA for all makes and models of trucks. Whether the truck is one year old or over fifteen years old, we have the clutch portfolio to provide our customers with cost effective solutions to keep their vehicle operating,” said Pawel Kepka, director, Aftermarket EMEA, Eaton’s Mobility Group.
Learn more about Eaton’s aftermarket solutions.
Eaton is an intelligent power management company dedicated to protecting the environment and improving the quality of life for people everywhere. We make products for the data center, utility, industrial, commercial, machine building, residential, aerospace, and mobility markets. We are guided by our commitment to do business right, to operate sustainably, and to help our customers manage power ─ today and well into the future. By capitalizing on the global growth trends of electrification and digitalization, we’re accelerating the planet’s transition to renewable energy sources, helping to solve the world’s most urgent power management challenges, and building a more sustainable society for people today and generations to come.
Eaton was founded in 1911 and has been listed on the New York Stock Exchange for more than a century. We reported revenues of $23.2 billion in 2023 and serve customers in more than 160 countries. For more information, visit www.eaton.com. Follow us on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240905507731/en/
Contacts
Thomas Nellenbach
Thomas Nellenbach
(216) 333-2876 (cell)
thomasjnellenbach@eaton.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom